Anderson T

Canadian Centre for Psychedelic Science, Toronto, Ontario, Canada.

9 papers · 2 preprints · ORCID

ArticlePsilocybin

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.

Beidas Z, Ragnhildstveit A, Blackman A +8

PreprintPsilocybin

Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial

Petranker R, Farb N, Syed O +4

ArticlePsilocybin

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.

Beidas Z, Ragnhildstveit A, Blackman A +9

PreprintPsilocybin

Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial

Beidas Z, Ragnhildstveit A, Blackman A +9

ArticleKetamine

A Case of Stress-Induced Cardiomyopathy After Ketamine Infusion.

Hart Z, Anderson T, Fanous H +2

ArticlePsilocybin

Keeping the promise: a critique of the current state of microdosing research.

Petranker R, Anderson T, Fewster EC +4

ArticlePsilocybin

Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.

Petranker R, Anderson T, Maier LJ +3

ArticlePsilocybin

Psychedelic Research and the Need for Transparency: Polishing Alice's Looking Glass.

Petranker R, Anderson T, Farb N

ArticlePsilocybin

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum D, Weissman C, Anderson T +4

ArticlePsilocybin

Psychedelic microdosing benefits and challenges: an empirical codebook.

Anderson T, Petranker R, Christopher A +5

ArticlePsilocybin

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.

Anderson T, Petranker R, Rosenbaum D +5